The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
IMFINZI AstraZeneca Pty Ltd
Product name
IMFINZI
Sponsor
Accepted date
Jan-2025
Active ingredients
durvalumab
Proposed indication
IMFINZI (durvalumab) is for the treatment of muscle invasive bladder cancer.
Application type
C (new indication)
Publication date
Jan-2025